The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It will only happen as traction and confidence in their technology grows and the need to use it to comply with regulatory requirements . There after it will the subject of their negotiating skills which are currently under the microscope and far from the best tool in their portfolio! Just my opinion but hopefully their confidence to put in deal making clauses will increase away from a lets do a deal at all costs mentality. They are saving bio's and small pharma cos significant amounts of expenditure in areas where attrition is greatest. Its looking good and long overdue!
Hi ants
I also asked that question regarding royalty sharing as that woukd be logical next step now we've helped Merck,Ankara and Bicycle accelerate and navigate navigate quickly through the phases and trials
Got to say I think his presentation was very good. I believe he's genuinely capable of taking PYC into profit and look forward to the development of Biostats and Personalised Medicine. The latter was always something that was clearly within their remit but has taken a long time to gain any form of traction. The rise in Regulatory requirements ( long overdue ) for non animal thus computer based modelling presents some very significant opportunities for the company. I believe 2024 will be a watershed in their development and subsequent success. Looking for innovative routes to royalty sharing should also be advanced. As always good luck!
Not surprised as the project revenues (£900k to 950k) is over 50% of the current cap and the pipeline having increased by 50% to £1.5mln is almost the same as today's market cap
From the latest interim RNS
The Directors are pleased that the Company is on track to meet expectations, which, if achieved, would mean a significant increase in total income compared with the financial year ended 30 June 2023
Yes Pete has been impressive in each of presentations and I agree,we've had far more buys today
It's the last day of Bed and ISA so maybe that's a factor ?
Giving an opinion on a company isn't provocation.
Ok Laura. Looks like Pete Sargent is putting in some good building blocks for the future. Hopefully we will get some traction soon. Not sure why we are down today.
Thankyou claret
Strange how these people get a kick out of being unpleasant..not sure why LSE allows it across all the platform
How are you doing claret
Laura. No point rising to provacation. We will have our day in the sun over next 6 months.
My instinct is telling me that they will take back Fernando Ortega (who was their senior PK/PD Modeller for several years ) for this role.
He had involvement with Dr Hitesh Mistry on a number of projects.
I think he left as his potential wasn’t being used as it should, now with this position he could be enticed back.
These are just my way of thinking, as usual I could be entirely wrong.
Small cap that
1 has increased revenues compared to the same period last year
2 cut losses
3 increased pipeline by 50%
4 increased clients
5 new CEO with vast experience in a particular field
Certainly not CPX that you were pumping in Nov and Dec 2023 and March 2024 despite it being down 95% and suspended
You still haven't said what happened to CPX ?
Currently suspended too after your latest pump
Kept afloat by issuing of shares. Comes a point when no one will buy them and it is the end. That point is closer and closer. All these contracts they win are just enough to pay part wages. It is never going to be profitable. It cant last much longer.
No doubt it will be high quality field
In the Q and A last month Peter stressed that the new role was so that was a dedicated IN HOUSE specialist to help manage the increasing client list
Applications for position now closed. Important they get the right candidate for this key role
How good to read your post!
Thanks Ralph
Appreciate
From their RNS March 2nd 2022.
Physiomics will be supporting Ankyra with modelling and simulation of ANK-101 in immune-oncology settings in support of its early development.
https://www.physiomics.co.uk/contract-award-9/
Kudos to PYC for helping Ankara and other clients get drugs to this stage quicker and with more precision. Wonder if PYC could start to do more revenue sharing models with future contracts ?
Ankyra has conducted an exploratory study of JEN-101 in dogs with advanced melanoma. “The canine study has confirmed that JEN-101 elicits potent biological activity in dogs with melanoma at doses that demonstrate good safety,” stated Rob Tighe, Chief Scientific Officer at Ankyra. He added that “the canine trial provides preliminary evidence that JEN-101 offers a therapeutic benefit in dogs with cancer and adds to the validation of our anchored therapy platform as an effective way to reduce the toxicities associated with powerful anti-tumor agents, such as IL-12.”
Under the terms of the agreement, Jenga will have an exclusive worldwide license to develop, manufacture, and commercialize JEN-101. Ankyra will receive an upfront payment and Jenga will take the lead on further development and commercialization of JEN-101. Ankyra will be eligible for regulatory and commercial milestone payments, plus royalties on worldwide sales.
Thanks Ralph,is this also one for the PYC assets please ? ANK101
Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors
Safety and tolerability to be determined at up to 10 study sites in the United States and Canada
March 05, 2024 08:00 AM Eastern Standard Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first patient dosed in the dose escalation cohort in a Phase 1 clinical study evaluating ANK-101, a tumor-directed, anchored immune medicine for solid tumors
Pyc reposted this about a licensing deal between Ankyra and Jenga Bioscience with their platform JEN-101 (formerly cANK-101 (PYC helped developed.)).
https://www.linkedin.com/posts/ankyratx_ankyra-therapeutics-and-jenga-biosciences-activity-7178508921270079488-WtE0?utm_source=share&utm_medium=member_desktop
In the bloodbath of AIM hugely indebted and bloated debt companies that make no effort to grow PYC is a breath of fresh air
Compared to HZM SND etc etc
I would say it's a buy, but not particularly fussed
If they are giving 1.29 for 500k for a larger sell then could suggest some behind-the-scenes demand. Maybe Peter Sargent after a few million (joke)
Current price range is 1.23 -1.33 for modest amounts
Weather i say its a sell ,or a buy ,its what i see ...i'm sure your all old enough to make your own judgements ,so misleading is not my game...i see it how i see it ...you want to see another way feel free..,volume and price go hand in hand ,that information i'll give you for free
In the recent presentation, JM touched on the development of the PYC precision dosing tool to predict GCSF levels (currently subject to Innovate-funded trials involving Beyond Blood/Blackpool Hospital) and also mentioned that they were in discussions with Dosemerx to see whether there may be 'some way to work with them to gather more data'
I get a feeling that both Dosemerx and PYC see good potential here